secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001549595-25-000005
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix reports preliminary cash $609.6M; plans pivotal CLL trials for NX-5948 in 2025
--------------------------------------------------------------------------------

- Preliminary cash and investments $609.6M as of Nov 30, 2024; runway into H1 2027.
- NX-5948 achieved 75.5% ORR in CLL patients; FDA Fast Track and EMA PRIME designations.
- Plans to initiate pivotal studies for NX-5948 in CLL in 2025; expand into WM and inflammatory indications.
- Gilead exercised option on IRAK4 degrader; Sanofi collaboration extended; STAT6 degrader candidate nomination expected H1 2025.
- Strengthened leadership: promoted Dr. O'Connor as CMO and Dr. Phiasivongsa as CTO; added Anil Kapur to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000005/0001549595-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000005/nrix-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer